Loading the section…
The price of enGene Therapeutics Inc. (ENGN) on October 9, 2026 is 1.73 USD, −2.81% on the day. Over 52 weeks the stock traded between 1.40 USD and 12.25 USD; the price now sits 3% of the way up that range. Over the past year the price changed by −76.65%. Market capitalization is 115.89 million USD, rank 83 among 128 stocks of the same industry with a known capitalization.
Closing prices for 9 October 2026
Next earnings report: none scheduled in the next five weeks · Earnings calendar
Change over the period shown (line colour): −79.13 %
enGene Therapeutics Inc. trades on Nasdaq under the ticker ENGN. The company belongs to the Health care sector. The trading history on this page starts on 1 February 2022.
Over the past 52 weeks ENGN has traded between 1.40 $ and 12.25 $. As of 9 October 2026 the price stood 3.04 % of the way from the 52-week low to the high.
Over one year ENGN shares fell 76.65 %; over six months they fell 75.97 %. Volatility over 90 days is 47.15 %. Dividends are not included: this is price change only, as of 9 October 2026.
The company reported a loss over the last four quarters, so a price-to-earnings ratio is not calculated. Price to book is 0.5, below the sector median of 2.5. Calculated from reports for the period ending 30 April 2026.
| Date | Open | High | Low | Close | Volume, shares |
|---|---|---|---|---|---|
| 9 October 2026 | 1.76 | 1.81 | 1.72 | 1.73 | 359,100 |
| 8 October 2026 | 1.75 | 1.79 | 1.68 | 1.78 | 1M |
| 7 October 2026 | 1.80 | 1.86 | 1.74 | 1.75 | 708,300 |
| 6 October 2026 | 1.87 | 1.87 |
The series is stated in the current share scale after splits; dividends are not included in the price
Based on the last 12 months of reports, through 30 April 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Address:4868 RUE LEVY, SUITE 220, SAINT-LAURENT, QC, H4R 2P1, CA
ENGN has a return on equity of −49.71 %, below the sector median of −41.68 %. Return on assets is −41.25 %, below the sector median of −32.11 %.
| 428M |
| RVMDRevolution Medicines, Inc. | 189.76 | +0.87 % | 409M |
| HALOHalozyme Therapeutics, Inc. | 110.42 | +0.53 % | 253M |
| BIIBBiogen Inc. | 225.71 | +3.33 % | 227M |
| KODKodiak Sciences Inc | 99.87 | +5.95 % | 219M |
| 1.80 |
| 1.80 |
| 361,700 |
| 5 October 2026 | 1.94 | 1.94 | 1.79 | 1.87 | 952,900 |
| 2 October 2026 | 2.00 | 2.02 | 1.93 | 1.94 | 690,100 |
| 1 October 2026 | 2.01 | 2.01 | 1.96 | 1.98 | 903,000 |
| 30 September 2026 | 1.97 | 2.02 | 1.93 | 2.00 | 1M |
| 29 September 2026 | 1.97 | 1.97 | 1.92 | 1.95 | 393,200 |
| 28 September 2026 | 1.96 | 1.98 | 1.90 | 1.97 | 332,200 |
| 25 September 2026 | 1.94 | 1.97 | 1.88 | 1.96 | 2M |
| 24 September 2026 | 1.99 | 1.99 | 1.91 | 1.92 | 796,300 |
| 23 September 2026 | 2.05 | 2.05 | 1.98 | 2.00 | 669,000 |
| 22 September 2026 | 1.96 | 2.08 | 1.96 | 2.05 | 1M |
| 21 September 2026 | 1.92 | 1.97 | 1.90 | 1.96 | 426,300 |
| 18 September 2026 | 1.92 | 1.93 | 1.89 | 1.91 | 401,000 |
| 17 September 2026 | 1.90 | 1.92 | 1.88 | 1.91 | 637,500 |
| 16 September 2026 | 1.90 | 1.92 | 1.88 | 1.91 | 579,300 |
| 15 September 2026 | 1.87 | 1.90 | 1.85 | 1.89 | 618,700 |
| 14 September 2026 | 1.80 | 1.88 | 1.80 | 1.87 | 460,500 |